MicroRNAs as mediators and therapeutic targets in chronic kidney disease

Nature Reviews Nephrology

Volumn 7, Issue 5, 2011, Pages 286-294

  Lorenzen, Johan M ^a   Haller, Hermann ^a   Thum, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; BINDING PROTEIN; DICER; MICRORNA; MICRORNA 192; MICRORNA 29A; MICRORNA 29B; MICRORNA 377; MICRORNA INHIBITOR; MICRORNA SPONGE; NEW DRUG; OLIGONUCLEOTIDE; RENIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ZINC FINGER E BOX BINDING HOMEOBOX 1 PROTEIN; ZINC FINGER E BOX BINDING HOMEOBOX 2 PROTEIN;

CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SELECTIVITY; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GLOMERULUS; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DEVELOPMENT; KIDNEY FIBROSIS; LUNG FIBROSIS; NEPHROSCLEROSIS; NONHUMAN; PODOCYTE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANIMALS; FIBROSIS; GENE THERAPY; HUMANS; KIDNEY FAILURE, CHRONIC; MICRORNAS; OLIGONUCLEOTIDES;

EID: 79955593914     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.26     Document Type: Review

References (67)

1. Eddy, A. A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 15, 290-301 (2000).
2. Boor, P., Ostendorf, T. & Floege, J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat. Rev. Nephrol. 6, 643-656 (2010).
3. Foley, R. N., Parfrey, P. S. & Sarnak, M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32, 112-119 (1998).
4. Kumar, V., Abbas, A. K. & Fausto, N. Pathologic Basis of Disease 87-118 (Elsevier Saunders, Philadelphia, 2005).
5. Quan, T. E., Cowper, S. E. & Bucala, R. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 8, 145-150 (2006). (Pubitemid 44623983)
6. Willis, B. C., du Bois, R. M. & Borok, Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. 3, 377-382 (2006). (Pubitemid 43845416)
7. Kalluri, R. & Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784 (2003). (Pubitemid 38063698)
8. Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M. & Cerami, A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1, 71-81 (1994).
9. Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287 (2008).
10. Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010).
11. Zeisberg, M. & Duffield, J. S. Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 21, 1247-1253 (2010).
12. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105, 13027-13032 (2008).
13. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 (2008).
14. Liu, G. et al. MiR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207, 1589-1597 (2010).
15. Thum, T. et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267 (2007). (Pubitemid 47196561)
16. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993). (Pubitemid 24014542)
17. MicroCosm Targets, Version 5. EMBL-EBI database [online], http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/ (2010).
18. Chiang, H. R. et al. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev. 24, 992-1009 (2010).
19. Cai, X., Hagedorn, C. H. & Cullen, B. R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10, 1957-1966 (2004). (Pubitemid 39557833)
20. Lee, Y. et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060 (2004). (Pubitemid 39472426)
21. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003). (Pubitemid 37187272)
22. Gregory, R. I. et al. The microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240 (2004). (Pubitemid 39545855)
23. Ambros, V. The functions of animal microRNAs. Nature 431, 350-355 (2004). (Pubitemid 39265675)
24. Valencia-Sanchez, M. A., Liu, J., Hannon, G. J. & Parker, R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20, 515-524 (2006). (Pubitemid 43345317)
25. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
26. Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).
27. Harvey, J. M. et al. Renal biopsy findings in hypertensive patients with proteinuria. Lancet 340, 1435-1356 (1992).
28. Zucchelli, P. & Zuccalà, A. Primary hypertension-how does it cause renal failure? Nephrol. Dial. Transplant. 9, 223-225 (1994). (Pubitemid 24111566)
29. Marcantoni, C., Ma, L. J., Federspiel, C. & Fogo, A. B. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 62, 172-180 (2002). (Pubitemid 34754060)
30. Kincaid-Smith, P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J. Hypertens. 22, 1051-1055 (2004). (Pubitemid 38720992)
31. Sequeira López, M. L., Pentz, E. S., Nomasa, T., Smithies, O. & Gomez, R. A. Renin cells are precursors for multiple cell types that switch to the renin phenotype when homeostasis is threatened. Dev. Cell. 6, 719-728 (2004). (Pubitemid 38579354)
32. Sequeira-López, M. L. et al. The microRNA-processing enzyme dicer maintains juxtaglomerular cells. J. Am. Soc. Nephrol. 21, 460-467 (2010).
33. Wang, G. et al. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am. J. Hypertens. 23, 78-84 (2010).
34. Tian, Z., Greene, A. S., Pietrusz, J. L., Matus, I. R. & Liang, M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18, 404-411. (2008). (Pubitemid 351347083)
35. Sun, Y. et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32, e188 (2004).
36. Bracken, C. P. et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68, 7846-7854 (2008).
37. Paterson, E. L. et al. The microRNA-200 family regulates epithelial to mesenchymal transition. ScientificWorldJournal 8, 901-904 (2008).
38. Liu, Y. et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 55, 974-982 (2010).
39. Fiedler, J., Gupta, S. & Thum, T. Micro-RNA based therapeutic approaches in the cardiovascular system. Cardiovasc. Ther. doi:10.1111/j.1755- 5922.2010.00220.x.
40. Fioretto, P., Steffes, M. W., Brown, D. M. & Mauer, S. M. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am. J. Kidney Dis. 20, 549-558 (1992). (Pubitemid 23031703)
41. Adler, S. Diabetic nephropathy: linking histology, cell biology, and genetics. Kidney Int. 66, 2095-2106 (2004).
42. Susztak, K., Raff, A. C., Schiffer, M. & Bottinger, E. P. Glucose induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225-233 (2006). (Pubitemid 43343319)
43. Krupa, A. et al. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 21, 438-447 (2010).
44. Liu, Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15, 1-12 (2004). (Pubitemid 38020692)
45. Comijn, J. et al. The two-handed E-box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267-1278 (2001). (Pubitemid 32607360)
46. Kato, M. et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-â-induced collagen expression via inhibition of E-box repressors. Proc. Natl Acad. Sci. USA 104, 3432-3427 (2007).
47. Kato, M. et al. TGF-â activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell. Biol. 11, 881-889 (2009).
48. Jiang, B. H. & Liu, L. Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res. 102, 19-65 (2009).
49. Suzuki, A., Nakano, T., Mak, T. W. & Sasaki, T. Portrait of PTEN: messages from mutant mice. Cancer Sci. 99, 209-213 (2008). (Pubitemid 351232668)
50. Chung, A. C., Huang, X. R., Meng, X. & Lan, H. Y. miR-192 mediates TGF-â/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 21, 1317-1325 (2010).
51. Wang, B. et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of TGFâ. Diabetes 59, 1794-1802 (2010).
52. Du, B. et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 584, 811-816 (2010).
53. Wang, Q. et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 22, 4126-4135 (2008).
54. Fleissner, F. et al. Asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ. Res. 107, 138-143 (2010).
55. Shi, S. et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am. Soc. Nephrol. 19, 2159-2169 (2008).
56. Wang, G. et al. Intrarenal expression of microRNAs in patients with IgA nephropathy. Lab. Invest. 90, 98-103 (2010).
57. Krützfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689 (2005).
58. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201 (2010).
59. Patrick, D. M. et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 120, 3912-3916 (2010).
60. Thum, T. et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J. Clin. Invest. 121, 461-462 (2011).
61. Kim, V. N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell. Biol. 6, 376-385 (2005). (Pubitemid 40637855)
62. Ebert, M. S. et al. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007). (Pubitemid 47338166)
63. Xiao, J. et al. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J. Cell. Physiol. 212, 285-292 (2007). (Pubitemid 47025616)
64. Sayed, D. et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell. 19, 3272-3282 (2008).
65. Krützfeldt, J. et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucl. Acids Res. 35, 2885-2892 (2007). (Pubitemid 47073627)
66. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Singlestranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574 (2002). (Pubitemid 35247837)
67. Jazbutyte, V. & Thum, T. MicroRNA-21: from cancer to cardiovascular disease. Curr. Drug Targets 11, 926-935 (2010).